AG
NBIX icon

AIA Group’s Neurocrine Biosciences NBIX Stock Holding History

AIA Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$210K Buy
+1,246
New +$185K ﹤0.01% 317
2026
Q1 		– Sell
-1,439
Closed -$204K – 353
2025
Q4 		$204K Sell
1,439
-108
-7% -$15.6K ﹤0.01% 332
2025
Q3 		$217K Sell
1,547
-234
-13% -$31.7K ﹤0.01% 394
2025
Q2 		$224K Sell
1,781
-150
-8% -$17.2K ﹤0.01% 322
2025
Q1 		$214K Buy
1,931
+230
+14% +$29.1K 0.01% 312
2024
Q4 		$232K Buy
+1,701
New +$210K 0.01% 288
2023
Q2 		– Sell
-2,105
Closed -$213K – 448
2023
Q1 		$213K Sell
2,105
-319
-13% -$33.2K 0.01% 317
2022
Q4 		$290K Buy
+2,424
New +$284K 0.02% 285
2022
Q3 		– Sell
-1,640
Closed -$160K – 436
2022
Q2 		$160K Buy
+1,640
New +$151K 0.01% 400

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

AIA Group's NBIX Position: Q2 2026 in Review

AIA Group opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,246 shares worth $210K. The stake represents ﹤0.01% of the portfolio and ranks #317 among its holdings. This is a return to the name: AIA Group previously reported a position in NBIX as recently as Q4 2025.

AIA Group first reported a position in NBIX in Q2 2022 and has held it in 9 quarters since. The position peaked at $290K in Q4 2022. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • AIA Group held 1,246 shares of Neurocrine Biosciences worth $210K as of Q2 2026.
  • Neurocrine Biosciences was a new AIA Group position in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of AIA Group's portfolio in Q2 2026, its #317 holding.
  • AIA Group first reported a position in Neurocrine Biosciences in Q2 2022 and has held it in 9 quarters since.
  • AIA Group's Neurocrine Biosciences position peaked at $290K in Q4 2022.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on AIA Group's 13F filing for Q2 2026, filed 31 Jul 2026.